What does Actio Biosciences do?
Actio Biosciences leverages advances in precision medicine and genetics to develop novel therapeutics that target both rare and common diseases. The company focuses on innovative approaches in clinical-stage research to address unmet medical needs.
How much did they raise?
The company raised $66M in Series B funding, with the round led by Regeneron Ventures and current investor Deerfield Management, alongside participation from existing investors Canaan, Droia Ventures, and Euclidean Capital.
What are their plans for the money?
Actio Biosciences intends to use the funds to further advance its lead programs, ABS-1230 and ABS-0871, which could potentially lead to new treatments for conditions such as Charcot-Marie-Tooth disease type 2C and KCNT1-related epilepsy, marking a significant step forward for precision medicine in rare diseases.
What have they achieved so far?
The company has already made progress in advancing its two lead rare disease programs, ABS-1230 and ABS-0871, demonstrating the potential to bring impactful therapies from development to a broader patient population.